دورية أكاديمية
أعرض في EDS

World Heart Federation Roadmap for Hypertension - A 2021 Update.

التفاصيل البيبلوغرافية
العنوان: World Heart Federation Roadmap for Hypertension - A 2021 Update.
المؤلفون: Jeemon P; Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandum, IN., Séverin T; World Heart Federation, Geneva, CH., Amodeo C; Universidade Federal de São Paulo (UNIFESP), São Paulo, BR., Balabanova D; London School of Hygiene & Tropical Medicine, London, GB., Campbell NRC; Libin Cardiovascular Institute of Alberta, University of Calgary, CA., Gaita D; Universitatea de Medicina si Farmacie Victor Babes, Timisoara, RO., Kario K; Jichi Medical University School of Medicine, Shimotsuke, Tochigi, JP., Khan T; University of Pretoria, ZA., Melifonwu R; Stroke Action Nigeria, Onitsha, Anambra State, NG., Moran A; Columbia University and Resolve to Save Lives, New York, US., Ogola E; University of Nairobi, KE., Ordunez P; Pan American Health Organization, Washington, DC, US., Perel P; London School of Hygiene & Tropical Medicine and World Heart Federation, Geneva, GB., Piñeiro D; Universidad de Buenos Aires, AR., Pinto FJ; Santa Maria University Hospital (CHULN), CAML, CCUL, Lisboa, PT., Schutte AE; University of New South Wales; The George Institute for Global Health, Sydney, AU., Wyss FS; Cardiovascular Technology and Services of Guatemala - CARDIOSOLUTIONS, Guatemala, GT., Yan LL; Duke Kunshan University, Kunshan, CN., Poulter NR; Imperial College London, London, GB., Prabhakaran D; London School of Hygiene & Tropical Medicine, London, GB.; Public Health Foundation of India, Gurugram, IN.
المصدر: Global heart [Glob Heart] 2021 Sep 10; Vol. 16 (1), pp. 63. Date of Electronic Publication: 2021 Sep 10 (Print Publication: 2021).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Ubiquity Press Country of Publication: England NLM ID: 101584391 Publication Model: eCollection Cited Medium: Internet ISSN: 2211-8179 (Electronic) Linking ISSN: 22118160 NLM ISO Abbreviation: Glob Heart Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : [London] : Ubiquity Press
Original Publication: [Oxford] : Elsevier Ltd.
مواضيع طبية MeSH: Cardiovascular Diseases* , Hypertension*/diagnosis , Hypertension*/epidemiology , Hypertension*/prevention & control, Cost-Benefit Analysis ; Humans ; Mass Screening
مستخلص: The World Heart Federation (WHF) Roadmap series covers a large range of cardiovascular conditions. These Roadmaps identify potential roadblocks and their solutions to improve the prevention, detection and management of cardiovascular diseases and provide a generic global framework available for local adaptation. A first Roadmap on raised blood pressure was published in 2015. Since then, advances in hypertension have included the publication of new clinical guidelines (AHA/ACC; ESC; ESH/ISH); the launch of the WHO Global HEARTS Initiative in 2016 and the associated Resolve to Save Lives (RTSL) initiative in 2017; the inclusion of single-pill combinations on the WHO Essential Medicines' list as well as various advances in technology, in particular telemedicine and mobile health. Given the substantial benefit accrued from effective interventions in the management of hypertension and their potential for scalability in low and middle-income countries (LMICs), the WHF has now revisited and updated the 'Roadmap for raised BP' as 'Roadmap for hypertension' by incorporating new developments in science and policy. Even though cost-effective lifestyle and medical interventions to prevent and manage hypertension exist, uptake is still low, particularly in resource-poor areas. This Roadmap examined the roadblocks pertaining to both the demand side (demographic and socio-economic factors, knowledge and beliefs, social relations, norms, and traditions) and the supply side (health systems resources and processes) along the patient pathway to propose a range of possible solutions to overcoming them. Those include the development of population-wide prevention and control programmes; the implementation of opportunistic screening and of out-of-office blood pressure measurements; the strengthening of primary care and a greater focus on task sharing and team-based care; the delivery of people-centred care and stronger patient and carer education; and the facilitation of adherence to treatment. All of the above are dependent upon the availability and effective distribution of good quality, evidence-based, inexpensive BP-lowering agents.
Competing Interests: Panniyammakal Jeemon is supported by the Wellcome Trust through a Wellcome Trust/DBT India Alliance Clinical and Public Health Intermediate Fellowship [IA/CPHI/14/1/501497]. Neil Poulter has received financial support from several pharmaceutical companies which manufacture BP-lowering agents, for consultancy fees (Servier), research projects, and staff (Servier, Pfizer) and for arranging and speaking at educational meetings (AstraZeneca, Lri Therapharma, Napi, Servier, Sanofi, Eva Pharma and Pfizer). He holds no stocks and shares in any such companies. Norman Campbell reports personal fees from Resolve to Save Lives (RTSL) outside the submitted work and is an unpaid member of World Action on Salt, Sugar and Health and an unpaid consultant on dietary sodium and hypertension control to numerous governmental and non-governmental organizations. Kazuomi Kario received research grant from A &D Co., Omron Helthcare Co., Fukuda Denshi Co., MSD K.K., Astellas Pharma Inc., Eisai Co., Otsuka Pharmaceutical Co., Otsuka Holdings Co., Sanofi K.K., Shionogi & Co., Sanwa Kagaku Kenkyusho Co., Daiichi Sankyo Co., Taisho Pharmaceutical Co., Ltd, Sumitomo Dainippon Pharma Co., Takeda Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Teijin Pharma, Boehringer Ingelheim Japan Inc., Pfizer Japan Inc., Fukuda Lifetec Co., Fukuda Lifetec Kanto Co., Bristol-Myers Squibb K.K., Mylan Co., Mochida Pharmaceutical Co., Roche Diagnostics K.K. and honoraria from Idorsia Pharmaceuticals Japan, Omron Healthcare Co., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Co., Terumo Corporation, Mylan EPD. Taskeen Khan is a staff member of the World Health Organization. The authors alone are responsible for the views expressed in this publication, and they do not necessarily represent those of the World Health Organization. Pedro Ordunez is a staff member of the Pan American Health Organization. The authors alone are responsible for the views expressed in this publication, and they do not necessarily represent those of the Pan American Health Organization. Aletta E Schutte has received speaker honoraria from Omron Healthcare, Servier, Takeda, Novartis and advisory board fees from Abbott, outside the submitted work.
(Copyright: © 2021 The Author(s).)
References: Am J Prev Med. 2016 May;50(5 Suppl 1):S34-S44. (PMID: 27102856)
J Multidiscip Healthc. 2020 Jul 03;13:571-580. (PMID: 32694916)
N Engl J Med. 2018 Apr 05;378(14):1291-1301. (PMID: 29527973)
Hypertens Res. 2020 Nov;43(11):1133-1134. (PMID: 32475981)
Int J Epidemiol. 2020 Jun 1;49(3):926-933. (PMID: 31722373)
J Hypertens. 2017 Aug;35(8):1529-1545. (PMID: 28520612)
BMJ Open. 2019 Nov 11;9(11):e028199. (PMID: 31719070)
Hypertension. 2017 Jul;70(1):85-93. (PMID: 28584013)
JAMA. 1997 May 28;277(20):1624-32. (PMID: 9168293)
J Hum Hypertens. 2018 Dec;32(12):814-824. (PMID: 30127487)
Environ Int. 2019 May;126:727-734. (PMID: 30878868)
Am J Prev Med. 2015 Nov;49(5):772-783. (PMID: 26477804)
J Hypertens. 2020 Jan;38(1):21-29. (PMID: 31790375)
Hypertension. 2015 Feb;65(2):291-8. (PMID: 25385758)
JAMA. 2003 Apr 23-30;289(16):2083-93. (PMID: 12709466)
Lancet. 2016 Nov 26;388(10060):2665-2712. (PMID: 27671667)
PLoS Med. 2018 May 1;15(5):e1002561. (PMID: 29715303)
Front Pharmacol. 2017 Mar 01;8:100. (PMID: 28298894)
Front Cardiovasc Med. 2016 Aug 02;3:26. (PMID: 27532038)
Hypertension. 2020 Aug;76(2):333-341. (PMID: 32419505)
J Clin Hypertens (Greenwich). 2020 Mar;22(3):438-444. (PMID: 31851429)
J Am Heart Assoc. 2013 Feb 01;2(1):e004473. (PMID: 23525435)
Lancet. 2020 Oct 17;396(10258):1223-1249. (PMID: 33069327)
Hypertension. 2017 Jan;69(1):128-135. (PMID: 27821618)
JAMA. 2002 Feb 27;287(8):1003-10. (PMID: 11866648)
JAMA. 2017 Sep 19;318(11):1016-1025. (PMID: 28975305)
Lancet Glob Health. 2018 Jul;6(7):e736-e743. (PMID: 29778399)
J Hypertens. 2015 Feb;33(2):221-9. (PMID: 25479029)
Mayo Clin Proc. 2014 Mar;89(3):327-34. (PMID: 24582191)
J Clin Hypertens (Greenwich). 2020 Feb;22(2):142-149. (PMID: 31967722)
J Hypertens. 2020 May;38(5):791-798. (PMID: 32102047)
Glob Heart. 2015 Jun;10(2):123-33. (PMID: 26213299)
PLoS One. 2017 Apr 18;12(4):e0174967. (PMID: 28419159)
Environ Pollut. 2020 Apr;259:113914. (PMID: 31935611)
Glob Heart. 2019 Mar;14(1):61-70. (PMID: 31036303)
Lancet. 2015 Nov 21;386(10008):2059-2068. (PMID: 26414968)
Int J Health Policy Manag. 2022 Mar 01;11(3):257-268. (PMID: 32702800)
Lancet Public Health. 2017 Feb;2(2):e108-e120. (PMID: 29253389)
Cochrane Database Syst Rev. 2020 May 7;5:CD013212. (PMID: 32378196)
Am J Prev Med. 2015 Dec;49(6):912-20. (PMID: 26590940)
Milbank Q. 1996;74(4):511-44. (PMID: 8941260)
J Hum Hypertens. 2019 Aug;33(8):562-565. (PMID: 31263179)
N Engl J Med. 2019 Jun 20;380(25):2429-2439. (PMID: 30883050)
Glob Heart. 2015 Jun;10(2):111-22. (PMID: 26213298)
Lancet. 2019 Aug 24;394(10199):652-662. (PMID: 31327566)
BMJ Glob Health. 2020 Sep;5(9):. (PMID: 32928800)
N Engl J Med. 2020 Feb 20;382(8):717-726. (PMID: 32074419)
Lancet Glob Health. 2019 Jun;7(6):e761-e771. (PMID: 31097278)
Lancet. 2019 Oct 5;394(10205):1231-1242. (PMID: 31488369)
J Hypertens. 2020 Jul;38(7):1235-1243. (PMID: 31990898)
Patient Prefer Adherence. 2018 Aug 14;12:1437-1449. (PMID: 30147302)
Eur Heart J Qual Care Clin Outcomes. 2016 Oct 1;2(4):237-244. (PMID: 29474713)
Glob Heart. 2018 Jun;13(2):83-91. (PMID: 29032937)
Glob Heart. 2019 Sep;14(3):215-240. (PMID: 31451236)
Int J Environ Res Public Health. 2020 Jul 30;17(15):. (PMID: 32751678)
Clin Hypertens. 2020 May 01;26:8. (PMID: 32377372)
J Clin Hypertens (Greenwich). 2019 Feb;21(2):208-216. (PMID: 30570209)
J Clin Hypertens (Greenwich). 2019 Dec;21(12):1744-1752. (PMID: 31769155)
Hypertension. 2003 Nov;42(5):878-84. (PMID: 12975389)
Health Policy Plan. 2018 Dec 1;33(10):1128-1143. (PMID: 30590543)
Lancet Glob Health. 2018 Jan;6(1):e66-e73. (PMID: 29241617)
Natl Med J India. 2018 May-Jun;31(3):129-132. (PMID: 31044756)
Hypertension. 2019 Oct;74(4):756-766. (PMID: 31446802)
J Clin Hypertens (Greenwich). 2020 Dec;22(12):2285-2295. (PMID: 33045133)
Glob Heart. 2020 Mar 30;15(1):26. (PMID: 32489799)
N Engl J Med. 1997 Apr 17;336(16):1117-24. (PMID: 9099655)
BMJ Open. 2018 Jan 5;8(1):e017351. (PMID: 29306878)
Lancet. 2019 Aug 24;394(10199):639-651. (PMID: 31327564)
Hypertension. 2021 Mar 3;77(3):806-812. (PMID: 33517681)
Curr Hypertens Rep. 2020 Aug 27;22(9):65. (PMID: 32852644)
J Clin Hypertens (Greenwich). 2020 Mar;22(3):331-343. (PMID: 31773883)
Hypertension. 2020 Jun;75(6):1334-1357. (PMID: 32370572)
Eur Heart J. 2019 Jul 1;40(25):2006-2017. (PMID: 31041440)
Nat Med. 2020 Mar;26(3):374-378. (PMID: 32066973)
J Clin Hypertens (Greenwich). 2020 Dec;22(12):2184-2191. (PMID: 33022866)
Glob Health Action. 2016 Feb 12;9:29041. (PMID: 26880152)
Glob Heart. 2019 Sep;14(3):197-214. (PMID: 31451235)
Environ Int. 2021 Jan;146:106174. (PMID: 33099063)
Cardiovasc J Afr. 2018 Sep/Oct;29(5):331-334. (PMID: 30395142)
Glob Heart. 2017 Mar;12(1):47-62. (PMID: 28336386)
Hypertens Res. 2016 Feb;39(2):88-94. (PMID: 26467494)
Am J Prev Med. 2014 Jul;47(1):86-99. (PMID: 24933494)
PLoS One. 2018 Dec 5;13(12):e0207511. (PMID: 30517130)
J Am Coll Cardiol. 2018 Oct 23;72(17):2054-2070. (PMID: 30336830)
J Clin Hypertens (Greenwich). 2016 Dec;18(12):1284-1294. (PMID: 27378199)
Hypertension. 2018 Jun;71(6):e13-e115. (PMID: 29133356)
PLoS One. 2012;7(10):e47064. (PMID: 23071713)
Eur Cardiol. 2015 Dec;10(2):95-101. (PMID: 30310433)
Curr Hypertens Rep. 2018 Aug 7;20(10):86. (PMID: 30088110)
PLoS One. 2018 Mar 14;13(3):e0192603. (PMID: 29538420)
BMC Health Serv Res. 2020 Sep 11;20(1):860. (PMID: 32917203)
J Clin Hypertens (Greenwich). 2017 Feb;19(2):198-204. (PMID: 27534595)
JAMA Netw Open. 2020 Sep 1;3(9):e2017507. (PMID: 32955574)
JAMA. 2013 Sep 4;310(9):959-68. (PMID: 24002282)
Int J Epidemiol. 2018 Jun 1;47(3):872-883i. (PMID: 29579276)
Am J Hypertens. 2020 Jul 18;33(7):620-628. (PMID: 32202625)
Lancet. 2011 Oct 1;378(9798):1219-30. (PMID: 21868086)
J Hypertens. 2020 Mar;38(3):395-399. (PMID: 31688462)
Glob Heart. 2017 Dec;12(4):273-284. (PMID: 28336387)
BMC Public Health. 2020 Apr 22;20(1):545. (PMID: 32321485)
J Occup Environ Med. 2015 Jun;57(6):682-6. (PMID: 26053367)
Can J Cardiol. 2020 May;36(5):732-739. (PMID: 32299635)
Lancet. 2017 Jan 7;389(10064):37-55. (PMID: 27863813)
J Clin Hypertens (Greenwich). 2020 Oct;22(10):1754-1756. (PMID: 32882074)
Clin Exp Hypertens. 2015;37(6):468-72. (PMID: 25815905)
Curr Opin Cardiol. 2010 Jul;25(4):366-72. (PMID: 20502323)
Glob Health Action. 2020 Dec 31;13(1):1806527. (PMID: 32867605)
BMC Cardiovasc Disord. 2019 Oct 21;19(1):231. (PMID: 31638907)
BMJ Glob Health. 2020 Apr 16;5(4):e002269. (PMID: 32377405)
J Hypertens. 2018 Oct;36(10):1953-2041. (PMID: 30234752)
Cardiovasc J Afr. 2020 Jan/Feb 23;31(1):9-15. (PMID: 31781714)
JAMA. 2017 Jan 10;317(2):165-182. (PMID: 28097354)
Hypertens Res. 2019 Sep;42(9):1235-1481. (PMID: 31375757)
BMJ. 2013 Apr 03;346:f1326. (PMID: 23558163)
Circulation. 2016 Aug 9;134(6):441-50. (PMID: 27502908)
Glob Heart. 2018 Mar;13(1):45-59. (PMID: 29042191)
BMJ Open. 2019 May 19;9(5):e025869. (PMID: 31110091)
J Hypertens. 2011 Mar;29(3):610-8. (PMID: 21157368)
Glob Heart. 2017 Sep;12(3):179-197.e5. (PMID: 28765036)
BMJ Glob Health. 2020 Jul;5(7):. (PMID: 32646854)
Hypertension. 2006 Feb;47(2):139-40. (PMID: 16380525)
J Hypertens. 2009 Jul;27(7):1472-7. (PMID: 19474763)
Hypertension. 2016 Jul;68(1):62-70. (PMID: 27245182)
J Clin Hypertens (Greenwich). 2021 Apr;23(4):755-765. (PMID: 33738969)
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. (PMID: 33309175)
Environ Res. 2020 Jul;186:109574. (PMID: 32668541)
J Clin Hypertens (Greenwich). 2016 Apr;18(4):260-1. (PMID: 26939059)
JAMA. 2020 Sep 22;324(12):1190-1200. (PMID: 32902588)
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004937. (PMID: 23633321)
N Engl J Med. 2015 Nov 26;373(22):2103-16. (PMID: 26551272)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust
فهرسة مساهمة: Keywords: WHF; World Heart Federation; hypertension; policy; raised BP; raised blood pressure
تواريخ الأحداث: Date Created: 20211025 Date Completed: 20211117 Latest Revision: 20231108
رمز التحديث: 20231108
مُعرف محوري في PubMed: PMC8447967
DOI: 10.5334/gh.1066
PMID: 34692387
قاعدة البيانات: MEDLINE
الوصف
تدمد:2211-8179
DOI:10.5334/gh.1066